Hatch, S., Swift, L., Caporali, S., Carter, R., Hill, E., Macgregor, T., . . . Sharma, R. (2014). XPF protein levels determine sensitivity of malignant melanoma cells to oxaliplatin chemotherapy: Suitability as a biomarker for patient selection.
توثيق أسلوب شيكاغو (الطبعة السابعة عشر)Hatch, S., et al. XPF Protein Levels Determine Sensitivity of Malignant Melanoma Cells to Oxaliplatin Chemotherapy: Suitability as a Biomarker for Patient Selection. 2014.
توثيق جمعية اللغة المعاصرة MLA (الإصدار التاسع)Hatch, S., et al. XPF Protein Levels Determine Sensitivity of Malignant Melanoma Cells to Oxaliplatin Chemotherapy: Suitability as a Biomarker for Patient Selection. 2014.
تحذير: قد لا تكون هذه الاستشهادات دائما دقيقة بنسبة 100%.